Tulsa, OK
Ketamine Therapy clinics in Tulsa
Tulsa has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Oklahoma requires DEA registration for ketamine prescribing; the state has a small but growing ketamine clinic footprint. Most Tulsa clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Tulsa only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Tulsa, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Tulsa sits in the affordable range: single IV infusions run 400 to 700 dollars, a full 6 session protocol lands at 2,400 to 4,200, and Spravato copays depend on insurance coverage. A reputable Tulsa ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Sevahealthcare
- PRP Therapy
- Ketamine Therapy
- Arthritis Treatment
- Migraine Treatment
- Stem Cell Therapy
Regulatory context
A note on Oklahoma's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
HB 2107 / Psilocybin Research (2023)
Authorized and funded psilocybin research for PTSD treatment; does not create therapeutic access. -
Oklahoma Uniform Controlled Dangerous Substances Act
Mirrors federal scheduling.
Oklahoma enforces federal scheduling. The Oklahoma State Board of Medical Licensure and Supervision oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Oklahoma PMP requires controlled substance reporting. Oklahoma Bureau of Narcotics and Dangerous Drugs requires a state controlled substance registration in addition to federal DEA.